Immunotherapy with checkpoint inhibitors is now considered standard first-line treatment in patients with metastatic melanoma, but there are still a range of factors to consider before choosing the therapeutic strategy for these patients.

In this podcast, Doctor Damien Kee from Austin Health speaks to Associate Professor Phil Parente, Director of Cancer Services at Eastern Health, about treatment options and management considerations in metastatic melanoma.

the limbic · Treatment choices in BRAF MT and wild-type metastatic melanoma
The views expressed in this podcast are the views of the presenters alone and are not necessarily reflective of the views of the sponsor. Please refer to the appropriate approved product information before prescribing any treatment mentioned in this podcast. Opdivo (nivolumab) Product Information can be found here. Please refer to www.pbs.gov.au for full PBS authority information.